Claims for Patent: 9,987,264

Summary for Patent: 9,987,264

Title:	Method and composition for treating a serotonin receptor-mediated condition
Abstract:	A method and composition for treating serotonin receptor-mediated conditions.
Inventor(s):	Polymeropoulos; Mihael H. (Potomac, MD), Baroldi; Paolo (Potomac, MD), Wolfgang; Curt (Germantown, MD)
Assignee:	Vanda Pharmaceuticals Inc. (Washington, DC)
Application Number:	15/242,468
Patent Claims:	1. A method of antagonizing a 5-HT.sub.2A receptor in an animal, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy- ]-3-methoxy-benzoic acid or pharmaceutically-acceptable salt thereof. 2. The method of claim 1, wherein the 5-HT.sub.2A receptor is not located in the brain. 3. The method of claim 1, wherein the 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof administered to the animal is between about 1 mg/day and about 500 mg/day. 4. The method of claim 3, wherein the effective amount is between about 5 mg/day and about 100 mg/day. 5. The method of claim 1, wherein the effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof administered to the animal is between about 0.01 mg/kg/day and about 10 mg/kg/day. 6. The method of claim 5, wherein the effective amount is between about 0.5 mg/kg/day and about 1.5 mg/kg/day. 7. The method of claim 1, wherein the animal is a human. 8. A method of antagonizing a 5-HT.sub.2A receptor in an animal, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy- ]-3-methoxy-benzoic acid or pharmaceutically-acceptable salt thereof, wherein the animal is suffering from a condition selected from the group consisting of: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attacks, stable angina, unstable angina, thrombotic stroke, a secondary ischemic event, atrial fibrillation, thrombosis, restenosis, asthma, diabetic nephropathy, and diabetic retinopathy. 9. The method of claim 8, wherein the secondary ischemic event is selected from the group consisting of: reversible ischemic neurological deficit and intermittent claudication. 10. The method of claim 8, wherein thrombosis is clot formation associated with at least one of the following: angioplasty, cardiac surgery, or atrial fibrillation. 11. The method of claim 8, wherein the condition is restenosis as a result of treatment with a medicated device. 12. The method of claim 11, wherein the medicated device is a medicated stent. 13. A method of antagonizing a 5-HT.sub.2A receptor in an animal, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy- ]-3-methoxy-benzoic acid or pharmaceutically-acceptable salt thereof; and administering to the animal at least one antithrombotic agent. 14. The method of claim 13, wherein the antithrombotic agent is selected from the group consisting of: clopidogrel bisulfate, streptokinase, alteplase, aprotinin, aspirin, and warfarin.

Details for Patent 9,987,264

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	12/29/1993		2039-02-26
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2039-02-26
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2039-02-26